BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, is seeking a pre-revenue listing on the Hong Kong Stock Exchange (HKEX) to raise capital to advance its BTK inhibitor, ICP-022, to an NDA filing in China by the end of this year.

CEO Christine Bunt of Verseau Therapeutics Inc. told BioWorld that the company has prepared a "wave" of prospects from its macrophage checkpoint modulator (MCM) platform ready to crash upon the shores of cancer therapy, with 23 novel targets in the hopper.

Aztherapies Inc., of Boston, said it closed a $26.3 million series C preferred equity financing co-led by Spinnaker Capital and Cosine, with participation from new and existing investors, including Drads Capital, IBS Capital and Wexford Capital.

It was at the constantly changing intersection of data science that Arsenal Biosciences Inc.'s CEO, Ken Drazan, found himself as he helped bring the company to life and to its $85 million series A fundraising.

DUBLIN – Amarna Therapeutics BV raised €10 million (US$11.1 million) in new financing to move its SV40-based gene therapy platform, SVac, toward the clinic.

Cyteir Therapeutics Inc., a Lexington, Mass.-based company exploiting synthetic lethality to fight cancer, is extending its series B financing with $40.2 million to support a recently launched phase I/II study of its lead candidate, CYT-0851, an oral small-molecule inhibitor of the protein RAD51. 

DUBLIN – Abalos Therapeutics GmbH raised €12 million (US$13.2 million) in series A funding to advance a distinctive approach to harnessing viruses for immuno-oncology applications.

Phathom Pharmaceuticals Inc., of Buffalo Grove, Ill., set terms for its proposed IPO, disclosing plans to offer 7.9 million common shares priced in a range of $18 to $20 for a raise of approximately $136.8 million at the midpoint. 

LONDON – Healx Ltd. has raised a $56 million series B after demonstrating its artificial intelligence-driven drug repurposing platform can systematically uncover treatments for rare diseases.

HONG KONG – Kobiolabs Inc., a microbiome-based venture from Seoul, South Korea, has secured a ?26.6 billion (US$22.2 million) investment. Founded in 2014, the venture has achieved ?193 billion of enterprise value.